RecruitingPhase 3NCT05994690

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Princess Maxima Center for Pediatric Oncology
Principal Investigator
Gertjan Kaspers, Prof. Dr.
Pediatric Oncologist
Intervention
Standard Intervention Rc(drug)
Enrollment
905 enrolled
Eligibility
18 years · All sexes
Timeline
20232035

Study locations (1)

Collaborators

European Commission

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05994690 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials